Longevity companies are finding workarounds to get their first human data
The cost of testing an experimental treatment in humans has grown so high that many promising longevity interventions never reach the clinic.
A Phase 1 clinical trial in the US or Europe can easily cost tens of millions of euros — before any evidence of efficacy has been established. The Good Manufacturing Practice (GMP) production requirements for the drug, the extensive safety data demanded by regulators, and the logistical challenge of recruiting participants make the threshold nearly insurmountable for small companies and academic groups. In the longevity sector, where many candidate interventions are relatively inexpensive existing molecules or early-stage biological preparations, the problem is particularly acute.
Mitrix Bio is one of the companies cited in this piece as an example. It is working on mitochondrial therapies — treatments aimed at repairing or enhancing the energy-producing organelles in cells, relevant to a broad range of aging-related conditions. Rather than following the standard regulatory pathway, the company is exploring alternatives: Right to Try legislation in the US (which gives terminally ill patients access to unapproved treatments), studies in countries with different regulatory frameworks, and expanded access programmes.
Faster learning, but at what cost?
The logic is understandable. Testing an intervention in seriously ill or dying patients under Right to Try yields initial human signals without the full regulatory burden. That data can then be used to attract investors and fund formal trials. It is not a substitute for controlled clinical studies, but a first step that would otherwise be unaffordable.
The downside is real. Data from uncontrolled settings are difficult to interpret. Placebo effects, patient selection bias, and the absence of a control group make it hard to distinguish genuine efficacy from noise. There are also ethical questions: are vulnerable patients adequately protected when treated outside formal trials with unproven interventions? Critics point out that the system sometimes functions more as a marketing instrument than as a scientific method.
A structural problem in the research landscape
What this story exposes is a structural mismatch between the time horizon of aging research and the funding logic of biotech. Aging is slow; trials that genuinely measure lifespan or healthspan are extraordinarily costly and long. The pressure to work faster, cheaper, and more flexibly is real — but the scientific standards that safeguard the quality of human data exist for good reason. How to resolve that tension is one of the most urgent unresolved questions in the field.